Literature DB >> 12116077

Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults.

Kenneth L McClain1, Jorge Mario Gonzalez, Rene Jonkers, Emanuela De Juli, Maarten Egeler.   

Abstract

BACKGROUND: Pulmonary involvement with Langerhans cell histiocytosis (LCH, formerly known as histiocytosis-X) presents as an interstitial process in children and adults either with or without symptoms. In contrast to other manifestations of LCH, most patients with pulmonary disease are adults. PROCEDURES: We reviewed the literature on pulmonary LCH to determine what were the clinical presentations, prognostic variables, and treatment options for this disease.
RESULTS: Although there are spontaneous remissions, a large number of patients have progressive pulmonary deficiency and experience significant morbidity if not mortality from the disease. The efficacy of steroid versus chemotherapy in halting the process remains controversial, even if smoking is taken into consideration.
CONCLUSIONS: A multicenter study of therapy for pulmonary LCH is the obvious answer to this dilemma. We propose that interested centers organize via the Histiocyte Society to plan and execute such a trial. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12116077     DOI: 10.1002/mpo.10064

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  2 in total

1.  Two smoking-related lesions in the same pulmonary lobe of squamous cell carcinoma and pulmonary Langerhans cell histiocytosis: A case report.

Authors:  Aysegul Gencer; Gizem Ozcibik; Fatma Gulsum Karakas; Ismail Sarbay; Sebnem Batur; Sermin Borekci; Akif Turna
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 2.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.